Prem Watsa
Fairfax Financial Holdings
Prem Watsa FStar Therapeutics Inc stake
total: 291
Fairfax Financial Holdings FSTX trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Held since:
- 2022 Q3
- Held for:
- 2 quarters
- Latest activity:
- 2023 Q1
According to 2026 Q2 report, Prem Watsa doesn't hold any FStar Therapeutics Inc (FSTX) shares. To date, the estimated cost basis is nearly $5.72 for "buy" trades and estimated average "sell" price is $6.31. Fairfax Financial Holdings first purchased FSTX in 2022 Q3, initially acquiring 24,399 shares. Since the initial investment in FStar Therapeutics Inc (FSTX), Fairfax Financial Holdings has made 2 more transactions.
When did Prem Watsa sell FStar Therapeutics Inc (FSTX)?
Prem Watsa sold off the entire FStar Therapeutics Inc (FSTX) position in 2023 Q1.
When did Prem Watsa buy FStar Therapeutics Inc (FSTX)?
Prem Watsa first invested in FStar Therapeutics Inc (FSTX) in 2022 Q3 at the reported quarter-end price of $5.12 per share.
What's the cost basis of Fairfax Financial Holdings's FSTX stake?
The estimated cost basis for FStar Therapeutics Inc (FSTX) stake is around $5.72 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $5.72
- Weighted AVG sell price:
- $6.31
Prem Watsa's historical trades in FStar Therapeutics Inc
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q1
|
0.00%
|
0
|
$6.31
|
|
-100% (-49,399)
|
-0.01%
|
|
2022 Q4
|
0.01%
|
49,399
|
$6.31
|
$311,708
|
+102.46% (+25,000)
|
+0%
|
|
2022 Q3
|
0.00%
|
24,399
|
$5.12
|
$125,000
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.